Latest Stories
ImpriMed Unveils Cancer Treatment Prediction Technology at EHA-SfPM Meeting, Expands AI-Driven Precision Medicine Services from Pets to Humans
Business Wire
ImpriMed Unveils Groundbreaking Cell-Sizing Method for High-Accuracy Feline Lymphoma Characterization in Veterinary Sciences
Business Wire
ImpriMed Launches Innovative AI-Driven Drug Response Predictions (DRP) Service to Guide Tailored Treatments, Meet Rising Demand in Veterinary Oncology
Business Wire
ImpriMed to Showcase Groundbreaking AI Research and Applications at Symposium on Artificial Intelligence in Veterinary Medicine (SAVY)
Business Wire
ImpriMed to Present Innovative Research at 2024 World Veterinary Cancer Congress
Business Wire
ImpriMed Raises $23 Million Series A Round to Expand its Revolutionary AI-Powered Cancer Treatment Technology
Business Wire
ImpriMed Wins Place at the Mayo Clinic Platform_Accelerate Immersive Program
EIN Presswire
40 Under 40 in Cancer Class of 2022 Recognizes Dr. Sungwon Lim, ImpriMed CEO & Co-Founder
EIN Presswire
ImpriMed Presents New Research Findings at The Veterinary Cancer Society (VCS) Mid-Year Conference
EIN Presswire
ImpriMed AI and machine learning is disrupting the veterinary oncology tools available for better treatment outcomes
EIN Presswire
ImpriMed CEO and Co-founder Dr. Sungwon Lim Wins Prestigious “Top Industry Leader” Award from Life Sciences Voice
EIN Presswire
ImpriMed Reports Significant Growth in 2021 with Pre-Series A Funding, New Product Launches, and Team Expansion
EIN Presswire
ImpriMed Launches Chemo Response Prediction and Immunophenotyping Services for Canine Lymphoma
GlobeNewswire
ImpriMed Raises $8M to Commercialize AI-Driven Personalized Drug Response Prediction Service in Pet Cancer Market
GlobeNewswire